Eloralintide (CAS 2883634-40-8) – Purity 99.90% | GMP Certified Factory

描述

Eloralintide, also known as LY-3841136, is a synthetic analog of amylin designed with a lipidated structure for enhanced stability and receptor affinity. It acts as a potent—but reversible—agonist of amylin receptors (AMYR), closely regulating satiety, delayed gastric emptying, and postprandial glucose levels. Its unique design makes it a powerful tool in obesity and type 2 diabetes research.

Early clinical research has indicated promising weight-loss potential (up to ~11% over 12 weeks in Phase I models) along with favorable tolerability. This GMP-manufactured product (?99.90% purity) is crafted specifically for laboratory research and exploration of metabolic pharmacology.

Product Specifications

Mechanism of Action & Research Applications

Eloralintide targets the amylin receptor (AMYR), mimicking natural amylin to suppress appetite, slow gastric emptying, and aid glucose control. Notably, early Phase I studies show significant weight reduction (2.6%–11.3% range) over a 12-week span in experimental models, with reduced adverse effects compared to other weight-loss peptides.

Research uses include:

• Investigating obesity treatments and metabolic regulation

• Examining synergy with GLP-1 receptor agonists

• Exploring amylin-based pathways in type 2 diabetes

• Modeling appetite and energy balance in metabolic studies

Side Effects (For Research Context Only)

Experimental application of Eloralintide may show:

• Decreased appetite and body weight in lab models

• Mild gastrointestinal effects (e.g., nausea, mild bowel changes)

• No severe or life-threatening responses observed in early models

These observations are experimental and should not be interpreted as clinical outcomes.

Disclaimer

Eloralintide is intended solely for laboratory research use. It is not approved for human, clinical, or veterinary use. Please handle under standard research safety protocols.